Cargando…

Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs

INTRODUCTION: Phenobarbital is a commonly used anticonvulsant for the treatment of canine epileptic seizures. In addition to its central nervous system (CNS) depressing effects, long-term phenobarbital administration affects liver function. However, broader metabolic consequences of phenobarbital tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottka, Claudia, Weber, Corinna, Müller, Elisabeth, Lohi, Hannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172515/
https://www.ncbi.nlm.nih.gov/pubmed/34076758
http://dx.doi.org/10.1007/s11306-021-01803-5
_version_ 1783702545512792064
author Ottka, Claudia
Weber, Corinna
Müller, Elisabeth
Lohi, Hannes
author_facet Ottka, Claudia
Weber, Corinna
Müller, Elisabeth
Lohi, Hannes
author_sort Ottka, Claudia
collection PubMed
description INTRODUCTION: Phenobarbital is a commonly used anticonvulsant for the treatment of canine epileptic seizures. In addition to its central nervous system (CNS) depressing effects, long-term phenobarbital administration affects liver function. However, broader metabolic consequences of phenobarbital treatment are poorly characterized. OBJECTIVES: To identify metabolic changes in the sera of phenobarbital-treated dogs and to investigate the relationship between serum phenobarbital concentration and metabolite levels. METHODS: Leftovers of clinical samples were used: 58 cases with phenobarbital concentrations ranging from 7.8 µg/mL to 50.8 µg/mL, and 25 controls. The study design was cross-sectional. The samples were analyzed by a canine-specific (1)H NMR metabolomics platform. Differences between the case and control groups were evaluated by logistic regression. The linear relationship between metabolite and phenobarbital concentrations was evaluated using linear regression. RESULTS: Increasing concentrations of glycoprotein acetyls, LDL particle size, palmitic acid, and saturated fatty acids, and decreasing concentrations of albumin, glutamine, histidine, LDL particle concentration, multiple HDL measures, and polyunsaturated fatty acids increased the odds of the sample belonging to the phenobarbital-treated group, having a p-value < .0033, and area under the curve (AUC) > .7. Albumin and glycoprotein acetyls had the best discriminative ability between the groups (AUC: .94). No linear associations between phenobarbital and metabolite concentrations were observed. CONCLUSION: The identified metabolites are known to associate with, for example, liver and CNS function, inflammatory processes and drug binding. The lack of a linear association to phenobarbital concentration suggests that other factors than the blood phenobarbital concentration contribute to the magnitude of metabolic changes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11306-021-01803-5.
format Online
Article
Text
id pubmed-8172515
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-81725152021-06-07 Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs Ottka, Claudia Weber, Corinna Müller, Elisabeth Lohi, Hannes Metabolomics Original Article INTRODUCTION: Phenobarbital is a commonly used anticonvulsant for the treatment of canine epileptic seizures. In addition to its central nervous system (CNS) depressing effects, long-term phenobarbital administration affects liver function. However, broader metabolic consequences of phenobarbital treatment are poorly characterized. OBJECTIVES: To identify metabolic changes in the sera of phenobarbital-treated dogs and to investigate the relationship between serum phenobarbital concentration and metabolite levels. METHODS: Leftovers of clinical samples were used: 58 cases with phenobarbital concentrations ranging from 7.8 µg/mL to 50.8 µg/mL, and 25 controls. The study design was cross-sectional. The samples were analyzed by a canine-specific (1)H NMR metabolomics platform. Differences between the case and control groups were evaluated by logistic regression. The linear relationship between metabolite and phenobarbital concentrations was evaluated using linear regression. RESULTS: Increasing concentrations of glycoprotein acetyls, LDL particle size, palmitic acid, and saturated fatty acids, and decreasing concentrations of albumin, glutamine, histidine, LDL particle concentration, multiple HDL measures, and polyunsaturated fatty acids increased the odds of the sample belonging to the phenobarbital-treated group, having a p-value < .0033, and area under the curve (AUC) > .7. Albumin and glycoprotein acetyls had the best discriminative ability between the groups (AUC: .94). No linear associations between phenobarbital and metabolite concentrations were observed. CONCLUSION: The identified metabolites are known to associate with, for example, liver and CNS function, inflammatory processes and drug binding. The lack of a linear association to phenobarbital concentration suggests that other factors than the blood phenobarbital concentration contribute to the magnitude of metabolic changes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11306-021-01803-5. Springer US 2021-06-02 2021 /pmc/articles/PMC8172515/ /pubmed/34076758 http://dx.doi.org/10.1007/s11306-021-01803-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Ottka, Claudia
Weber, Corinna
Müller, Elisabeth
Lohi, Hannes
Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs
title Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs
title_full Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs
title_fullStr Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs
title_full_unstemmed Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs
title_short Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs
title_sort serum nmr metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172515/
https://www.ncbi.nlm.nih.gov/pubmed/34076758
http://dx.doi.org/10.1007/s11306-021-01803-5
work_keys_str_mv AT ottkaclaudia serumnmrmetabolomicsuncoversmultiplemetabolicchangesinphenobarbitaltreateddogs
AT webercorinna serumnmrmetabolomicsuncoversmultiplemetabolicchangesinphenobarbitaltreateddogs
AT mullerelisabeth serumnmrmetabolomicsuncoversmultiplemetabolicchangesinphenobarbitaltreateddogs
AT lohihannes serumnmrmetabolomicsuncoversmultiplemetabolicchangesinphenobarbitaltreateddogs